Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Analysts are estimating that Soleno Therapeutics will report an earnings per share (EPS) of $-0.53. The market awaits Soleno Therapeutics's announcement, with hopes high for news of surpassing ...

Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

--Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced updates to its Board of Directors.

Recent health news highlights Britain's decision not to support the bioethanol industry, Berkshire Hathaway's investment in ...

REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 Provided by GlobeNewswire Jul 10, 2025, 3:00:37 AM ...

The UK's bioethanol industry faces collapse due to the trade deal with Trump, leaving the government opting not to intervene.

REDWOOD CITY, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...